Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Teleflex (TFX), Sanofi (SNYNF) and Neurocrine (NBIX).
Teleflex (TFX)
Needham analyst Michael Matson maintained a Buy rating on Teleflex today and set a price target of $445.00. The company’s shares closed last Thursday at $398.66, close to its 52-week high of $414.72.
According to TipRanks.com, Matson is a 5-star analyst with an average return of 15.4% and a 69.1% success rate. Matson covers the Healthcare sector, focusing on stocks such as Axonics Modulation Technologies, Zimmer Biomet Holdings, and Cardiovascular Systems.
Teleflex has an analyst consensus of Strong Buy, with a price target consensus of $450.75, a 15.6% upside from current levels. In a report issued on January 27, JMP Securities also maintained a Buy rating on the stock with a $440.00 price target.
See today’s analyst top recommended stocks >>
Sanofi (SNYNF)
In a report released today, Peter Welford from Jefferies maintained a Buy rating on Sanofi, with a price target of EUR110.00. The company’s shares closed last Thursday at $94.28.
Welford has an average return of 7.1% when recommending Sanofi.
According to TipRanks.com, Welford is ranked #529 out of 7271 analysts.
Currently, the analyst consensus on Sanofi is a Moderate Buy with an average price target of $116.45, representing a 23.5% upside. In a report issued on January 26, J.P. Morgan also maintained a Buy rating on the stock with a EUR93.00 price target.
Neurocrine (NBIX)
In a report released today, Joseph Stringer from Needham maintained a Hold rating on Neurocrine. The company’s shares closed last Thursday at $114.55.
According to TipRanks.com, Stringer is a 3-star analyst with an average return of 23.5% and a 66.7% success rate. Stringer covers the Healthcare sector, focusing on stocks such as Apellis Pharmaceuticals, Annexon Biosciences, and Stoke Therapeutics.
Currently, the analyst consensus on Neurocrine is a Moderate Buy with an average price target of $123.79, a 9.4% upside from current levels. In a report issued on February 1, Mizuho Securities also maintained a Hold rating on the stock with a $117.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
